Michael T Milano

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 59:445-53. 2004
  2. ncbi request reprint Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 61:1096-106. 2005
  3. ncbi request reprint Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 1470, USA
    Int J Radiat Oncol Biol Phys 64:382-91. 2006
  4. ncbi request reprint Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions
    Michael T Milano
    Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 28:1141-51. 2006
  5. ncbi request reprint Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer
    Joseph K Salama
    Departments of Radiation and Cellular Oncology, University of Chicago, 5758 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Cancer J 11:140-6. 2005
  6. ncbi request reprint Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 63:354-61. 2005
  7. ncbi request reprint Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 10:4922-32. 2004
  8. ncbi request reprint Reirradiation of recurrent head and neck cancers with curative intent
    Steven J Chmura
    Department of Radiation and Cellular Oncology, 5758 S Maryland, MC 9006, Chicago, IL 60637, USA
    Semin Oncol 31:816-21. 2004
  9. ncbi request reprint Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity
    Ashesh B Jani
    Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Urology 67:147-51. 2006
  10. ncbi request reprint Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review
    Johnny Kao
    Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Treat Rev 29:21-30. 2003

Detail Information

Publications13

  1. ncbi request reprint Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 59:445-53. 2004
    ..To assess the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) in pancreatic and bile duct (cholangiocarcinoma) malignancies...
  2. ncbi request reprint Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 61:1096-106. 2005
    ..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck...
  3. ncbi request reprint Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 1470, USA
    Int J Radiat Oncol Biol Phys 64:382-91. 2006
    ....
  4. ncbi request reprint Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions
    Michael T Milano
    Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 28:1141-51. 2006
    ..Building on the present clinical experience, future directions include more directed efforts at reducing toxicity, with better planning software and planning techniques...
  5. ncbi request reprint Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer
    Joseph K Salama
    Departments of Radiation and Cellular Oncology, University of Chicago, 5758 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Cancer J 11:140-6. 2005
    ..A phase I study was conducted to determine the maximum tolerated dose and dose-limiting toxicities of this regimen...
  6. ncbi request reprint Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 63:354-61. 2005
    ..To assess survival, local control, and toxicity of intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the anal canal...
  7. ncbi request reprint Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 10:4922-32. 2004
    ..In the present phase I trial, gemcitabine, a novel antimetabolite with strong radiation-enhancing activity, replaces hydroxyurea. We sought to determine the recommended phase II dose and clinical efficacy in poor-prognosis HNC patients...
  8. ncbi request reprint Reirradiation of recurrent head and neck cancers with curative intent
    Steven J Chmura
    Department of Radiation and Cellular Oncology, 5758 S Maryland, MC 9006, Chicago, IL 60637, USA
    Semin Oncol 31:816-21. 2004
    ..Reirradiation with chemotherapy is appropriate for patients with a goal of long-term local control of disease and curative intent, despite the risk of significant acute and late toxicities...
  9. ncbi request reprint Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity
    Ashesh B Jani
    Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Urology 67:147-51. 2006
    ..To provide a single-institution analysis of the influence of pelvic intensity-modulated radiotherapy (RT) on acute genitourinary (GU) and gastrointestinal (GI) toxicity...
  10. ncbi request reprint Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review
    Johnny Kao
    Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Treat Rev 29:21-30. 2003
    ..The results of reirradiation in recurrent head and neck cancer and the prognostic factors predicting outcome in this patient population are reviewed...
  11. ncbi request reprint Intensity-modulated radiotherapy and the Internet
    David A Schomas
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 101:412-20. 2004
    ..The objective of the current study was to evaluate the content and quality of patient-oriented information regarding intensity-modulated radiotherapy (IMRT) on the Internet...
  12. ncbi request reprint Stereotactic Body Radiation Therapy (SBRT) for lung metastases
    Paul Okunieff
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
    Acta Oncol 45:808-17. 2006
    ..Median survival time and progression-free survival both appear better than that achieved with standard care alone. Long-term progression-free survival can be seen in a subset of patients when all tumors are targeted...
  13. ncbi request reprint Normal tissue tolerance dose metrics for radiation therapy of major organs
    Michael T Milano
    Department of Radiation Oncology and James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Semin Radiat Oncol 17:131-40. 2007
    ..This review summarizes the published clinical data on the risk of late toxicity as a function of quantitative dose metrics and attempts to offer suggested dose constraints for radiation treatment planning...